TB-500 Unlocking Healing Potential

TB-500 solves a different problem than BPC-157. Where BPC-157 drives local repair at the injury site, TB-500 coordinates the logistics: getting the right cells to the right place and organizing them into functional architecture rather than scar tissue. It maintains a reserve pool of structural building blocks (G-actin monomers) inside cells, enabling rapid deployment when repair demands it. Cells that were stuck start moving. Chaotic scar starts organizing.

TB-4, the parent molecule, has Phase 1 human safety data (84 healthy volunteers, doses up to 25 μg/kg daily for 10 days, no serious adverse events⁷) and Phase 3 efficacy data in corneal wound healing. Thymosin beta-4 is among the most conserved peptides across species, nearly identical from fish to mammals, which points to an ancient and conserved role in tissue repair.

Where TB-500 wins: large-area tissue damage, injuries with multiple affected sites, and the Wolverine Stack pairing where both mechanisms compound. TB-500 is a 7-amino-acid fragment of thymosin beta-4, and most products labeled "TB-500" contain full-length TB-4 (43 amino acids) instead. Both have repair activity, and the difference matters for what the molecule can do and for which numbers apply to it.

That second part is where the field gets it wrong most often. The widely circulated 2–4 mg dose belongs to full-length thymosin beta-4, and TB-4 trial data does not transfer to a TB-500 vial: different molecule, different mass. The derived position for the fragment is 1–2.5 mg per dose, two to three times weekly, for a weekly target of 4–6 mg. Effects are slower than BPC-157, with morning stiffness decreasing in weeks 1–2 and load tolerance improving through weeks 5–8.

What TB-500 Is

Thymosin beta-4 (TB-4) is a 43-amino-acid protein first isolated from the thymus gland in the 1960s, but subsequent research found it everywhere: platelets, wound fluid, developing tissue, regenerating muscle. It is among the most conserved peptides across species: the human version is nearly identical to versions found in fish, amphibians, and mammals, which points to an ancient and conserved role in tissue repair.

TB-500 is a 7-amino-acid fragment (positions 17–23, sequence LKKTETQ) of that parent molecule, the specific region responsible for actin binding and cell migration. It was isolated because this short sequence concentrates the tissue repair activity of the full protein into a smaller, synthetically simpler compound (~800 Da vs ~4,900 Da for full-length TB-4).

The naming problem: Most vendors selling "TB-500" are actually selling full-length TB-4. Doping control analysis of commercial products confirmed this directly: vials labeled "TB-500" contained the full 43-amino-acid protein¹³. The fragment is harder to synthesize and less commercially available. Both have tissue repair activity, since TB-4 contains the same active region plus additional sequence, but they are not the same compound. On the Certificate of Analysis, a molecular weight of ~4,900 Da marks TB-4 regardless of label. See the FAQ below for the verification detail.

This guide uses "TB-500" to refer to the fragment and "TB-4" for the full molecule. The dose bands are molecule-specific and are not interchangeable, and the two are not mechanistically identical, because TB-4 carries active sites that the fragment does not (see How It Works). Which one is in the vial determines the available effects and the injection routing (see Dosing).

Unlike growth factors that primarily instruct cells to proliferate, TB-500 directs where cells go and how they arrange themselves once they arrive. Addressing this second bottleneck, cellular choreography, is what distinguishes TB-500 from most other repair compounds.

How TB-500 Works

TB-500 and TB-4 share the actin-binding domain, but they’re not mechanistically identical. TB-4 carries active sites the fragment doesn’t, most importantly an anti-fibrotic fragment (Ac-SDKP) that TB-500 lacks entirely. Where it matters, the distinction is noted below.

Enables rapid cell migration

Inside every cell, actin proteins form the structural scaffolding that enables movement and division. Actin exists in two states: monomers (G-actin) floating freely in the cytoplasm, and filaments (F-actin) assembled into functional structures.

The LKKTETQ sequence, present in both TB-500 and TB-4, binds G-actin monomers, preventing premature assembly into filaments (actin sequestration¹). This creates a reserve pool that cells can rapidly deploy when they need to move, divide, or reorganize. Without this reserve, cells respond sluggishly to repair signals, having to manufacture new actin rather than draw from inventory.

The practical result: fibroblasts migrate efficiently into injured tendons. Endothelial cells extend into damaged zones to form new blood vessels. Keratinocytes advance across wound surfaces. In each case, the rate-limiting step shifts from "can the cell move?" to "where should it go?"

A 2024 finding adds nuance: TB-500 undergoes serial C-terminal cleavage after injection, and one of its metabolites, Ac-LKKTE, showed wound healing activity in its own right (Yang et al. 2024⁹). TB-500 may function partly as a prodrug, with degradation products contributing to the biological effect. This also helps explain why activity persists well beyond TB-500's short plasma half-life.

Builds new blood vessels

Beyond enabling cell migration generally, fragment 17–23 specifically promotes blood vessel formation. Endothelial cells, the cells lining blood vessels, respond by migrating into injured areas and assembling into tube structures (endothelial migration and tube formation²).

This mechanism complements but differs from BPC-157's approach to angiogenesis. BPC-157 upregulates VEGF (the signal to build vessels); TB-500 enables the endothelial cells to physically move and organize into functional capillaries. The two peptides address different parts of the same process, which is why they combine effectively.

Reduces excessive scarring

This effect comes from TB-4, not the TB-500 fragment. A review of TB-4 fragment functions mapped three distinct active sites within the molecule¹⁵, and anti-fibrotic activity belongs to Ac-SDKP, a 4-amino-acid fragment (positions 1–4) released when TB-4 is enzymatically processed. Ac-SDKP suppresses TGF-beta/Smad2/3 signaling and blocks myofibroblast differentiation, the cells responsible for excessive scar formation³.

This processing requires a two-step enzymatic cascade: meprin-alpha first cuts TB-4 into shorter intermediates, then prolyl oligopeptidase (POP) releases Ac-SDKP from those intermediates (Kumar & Bhatt 2016¹⁰). POP cannot cleave full-length TB-4 directly, because the 43-amino-acid protein exceeds its ~30 amino acid structural limit.

In cardiac, hepatic, and renal fibrosis models, TB-4 reduced pathological collagen deposition without impairing necessary tissue repair. TB-500 does not contain the Ac-SDKP sequence and does not produce this anti-fibrotic effect. If scar reduction is a primary goal, TB-4 (the full molecule) is what the evidence supports.

Shifts immune cells toward repair

Immune cells called macrophages play two distinct roles during healing. Early after injury, M1 macrophages drive inflammation, clearing debris, fighting infection, and recruiting other immune cells. Later, M2 macrophages promote tissue remodeling: organizing new matrix, resolving inflammation, and coordinating repair.

TB-4 promotes the shift from inflammatory M1 toward reparative M2 macrophages (macrophage polarization⁴). This transitions healing from acute inflammation to productive repair. However, this effect has been studied with full-length TB-4, not the isolated 17–23 fragment. Whether TB-500 alone drives macrophage polarization is unknown — it may require the Ac-SDKP fragment or other regions of the full molecule.

Applications

Tendon and ligament healing

Stalled healing presents a familiar pattern: tissue feels stiff and tight, range of motion is limited, every attempt to load triggers setbacks. Morning stiffness takes 20+ minutes to resolve. "First-step" pain persists despite time and rest.

This persistent dysfunction reflects failed cell migration and organization. Repair cells can’t reach damaged tissue efficiently. Those that arrive don’t organize properly. The result: disorganized scar tissue, adhesions between tissue planes, mechanical dysfunction that doesn’t resolve on its own.

Physical therapy applies mechanical force but can’t fix cellular choreography. Manual therapy temporarily breaks adhesions but doesn’t address why cells didn’t organize correctly. Surgery creates new trauma without solving the underlying migration failure.

TB-500 addresses the bottleneck directly by enabling cell migration and organization so the repair cascade proceeds through stalled phases.

What to expect:

• Weeks 1-2: Morning stiffness and "first-step" pain decrease
• Weeks 3-4: Range of motion improves, tissue planes separate properly
• Weeks 5-8: Eccentric loading tolerance increases, progressive loading becomes possible

Wound healing

TB-500 accelerates wound closure through multiple coordinated effects: keratinocytes migrate faster to cover wound surfaces, endothelial cells form new vasculature within the wound bed, fibroblasts deposit collagen in organized patterns rather than chaotic scar.

A trial of 72 patients with chronic venous ulcers found approximately 25% complete wound closure at 3 months using 0.03% thymosin beta-4 gel⁵. While modest by pharmaceutical standards, this represents meaningful improvement in wounds that had resisted conventional treatment.

The preclinical literature is more extensive: accelerated dermal wound closure, enhanced cellular migration, and organized tissue remodeling rather than scar formation.

Corneal healing, the most advanced human data

The cornea provides the clearest human evidence for TB-4 efficacy, precisely because the cornea lacks blood vessels. This eliminates the confound of improved perfusion, so any healing effect must come from direct cellular action.

The SEER-1 Phase 3 trial enrolled 18 patients with neurotrophic keratopathy, a condition where corneal nerves are damaged and the healing reflex is impaired. Complete corneal healing reached 60% (6 of 10) on thymosin beta-4 against 12.5% (1 of 8) on placebo. At Day 43, 50% of treated patients maintained complete healing versus 0% of placebo patients (p=0.0359)⁶. Eighteen patients is a small trial, and this is the parent molecule rather than the fragment.

The result matters beyond ophthalmology because the cornea has no blood vessels, so a healing effect there cannot be explained by improved perfusion.

Cardiac repair (preclinical)

In mouse models of myocardial ischemia (heart attacks), TB-4 activated signaling pathways that promote cardiac cell migration and survival (integrin-linked kinase pathway³). It also influenced epicardial progenitor cells, a population that contributes to cardiac regeneration.

This application remains preclinical only. But it establishes mechanistic credibility: the same actin-sequestration and cell-migration effects observed in tendons and wounds operate in cardiac tissue.

Dosing

The peptide calculator converts vial concentration to injection volume.

Protocol table

The derived position is a flat schedule rather than a loading-and-maintenance structure. Neither anchor behind the weekly band supports front-loading, and no efficacy endpoint in humans anchors the band at all.

The full defensible envelope runs 2.0-7.5 mg per week, and a conservative first cycle sits at 1-1.5 mg twice weekly, or 2-3 mg per week. Above 6 mg per week exceeds both of the anchors the band rests on, which makes it a deliberate exception rather than a default.

Where the weekly band comes from

The band rests on two veterinary anchors that disagree with each other by 2.6x. An equine protocol scales to 2.29 mg per week for a 70 kg human. Back-calculation from a 5 mg greyhound dose gives 5.91 mg per week. The derived 4-6 mg target sits between them.

Those are the anchors. There is no human efficacy endpoint anchoring this band, which is the reason the ceiling matters more than the midpoint: exceeding 6 mg per week leaves both animal references behind with nothing on the other side.

The 2-4 mg attribution error

A 2-4 mg dose is widely printed as TB-500's, and it belongs to full-length thymosin beta-4 instead. Copying it onto a TB-500 vial merges the parent molecule into the fragment. The two differ in mass by roughly a factor of six (~800 Da versus ~4,900 Da), so a milligram figure derived for one does not describe the same molar exposure in the other. TB-4 trial data does not transfer to a TB-500 vial.

Cycle length

Four to six weeks, then stop and assess. Any repeat follows a break rather than a taper, since there is no maintenance phase in the derived position to taper into.

Route

Subcutaneous (SC) or intramuscular (IM) injection both work. IM is the route of choice in protocols for deeper musculoskeletal injuries.

Protocols favor an injection site near the injury where the anatomy allows, and the effort is small enough to be worth making. For injuries in difficult-to-reach locations (spine, deep hip), abdominal or thigh injection is the practical alternative.

The reasoning here is not the same as BPC-157's, and it should be read as a hypothesis rather than an established mechanism. The fragment carries a small positive charge patch. Tendon, cartilage and disc are built on strongly negatively charged matrix, so the proposal is that the fragment is drawn into that matrix and held there rather than washed straight out. Reconstituting to the smallest practical volume follows from the same idea.

The hypothesis has a clean falsification test: if matrix charge is what retains the fragment, then retention should scale with tissue charge density and should drop when that charge is reduced. Nobody has run that experiment. What has been shown is narrower and comes from the parent molecule: free systemic TB-4 produced no functional improvement at the same total dose as a locally-targeted formulation in cardiac repair¹¹, and sustained local release via scaffold achieved 93% wound closure in diabetic wounds¹².

Both TB-500 and TB-4 enter systemic circulation rapidly, so neither stays local in any absolute sense. Near-injury placement is a defensible default, not a way of aiming the compound at an injury.

Why TB-500 is not daily

BPC-157 works at nanogram thresholds — it triggers signaling cascades catalytically, meaning a small amount flips the switch. TB-500 works by mass-action: it physically binds G-actin monomers one-to-one, sequestering them into reserve pools. Meaningfully raising the cellular reserve takes milligram-scale bolus doses to bind enough actin.

Once those reserves are established, the biological effect persists for days even though the peptide itself clears in hours (half-life 0.5–2.1 hours IV⁷). The actin pools do not disappear when TB-500 clears; they remain available until the cell draws on them for migration or division. This is the mechanistic argument for 1–2.5 mg doses two to three times per week rather than smaller daily ones: peak concentration drives the binding event, and the downstream effect sustains itself between doses.

The two-to-three-times-weekly frequency fits that mechanism, but it was not derived from pharmacokinetic modelling, and the weekly band behind it rests on two veterinary anchors rather than a human efficacy endpoint. With full-length TB-4 (the molecule in most vials), the actin-binding logic carries over, but the milligram figures do not: TB-4 numbers describe a molecule roughly six times the fragment’s mass.

Why there is no loading phase

Front-loading has an appealing story behind it: the early healing phases are when cells migrate into the injury and begin organizing, so more peptide early should buy more of that. Nothing in the evidence tests it. Neither veterinary anchor behind the weekly band used a loading structure, and there is no human efficacy endpoint to read a phase effect from.

A flat 4–6 mg weekly target over 4–6 weeks is what the anchors support, so that is the derived position. A loading-and-maintenance split adds structure the data cannot justify, and it front-loads exposure above the ceiling both anchors imply.

Side Effects and Safety

Side effect profile

Reported side effects are mild and infrequent at the doses described above. The record behind that statement is uncontrolled use rather than trial surveillance, and the one formal safety trial used the parent molecule.

Phase 1 human safety data

The most reassuring safety data comes from the Phase 1 trial of recombinant thymosin beta-4 (Wang et al. 2021): 84 healthy volunteers across single-dose (54 subjects, up to 25 μg/kg) and multiple-dose (30 subjects, up to 5 μg/kg daily for 10 days) arms, with no serious adverse events or dose-limiting toxicity⁷.

An important caveat: this trial used recombinant TB-4 (the full-length protein), not synthetic TB-500 (the fragment). The synthetic TB-500 and TB-4 sold by peptide suppliers have not been independently characterized in formal human safety studies. The Wang et al. data provides the closest available human safety reference, but it is not a direct validation of the products most people are using.

Contraindications

Absolute:

• Active cancer or malignancy within 2 years (TB-500 promotes angiogenesis and cell migration)
• Pregnancy or breastfeeding (insufficient safety data)
• Proliferative retinopathy (angiogenesis may worsen pathology)
• Surgery planned or recent (<2 weeks) (excessive angiogenesis may complicate healing)

Relative (use with medical supervision):

• Concurrent corticosteroid use (steroids oppose tissue repair mechanisms)
• Severe cardiovascular disease
• Active autoimmune conditions
• Therapeutic anticoagulation

Regulatory status

TB-500 is a research peptide without FDA approval. It is not a controlled substance but cannot be marketed for human therapeutic use in the United States.

On 23 July 2026, the Pharmacy Compounding Advisory Committee voted to recommend adding TB-500 to the 503A Bulks List, against the FDA’s own staff, who had recommended against listing. The same meeting reached the same result separately for BPC-157 and KPV. Reported vote counts are contested, so no tally is given here. Operative status is recommended for listing, pending FDA action: a committee recommendation is not a rule, notice-and-comment rulemaking follows and can take over a year, and this is an access-pathway question rather than therapeutic approval. Compounding remains unapproved new drug manufacturing under the FD&C Act in the meantime.

WADA prohibits TB-500 for competitive athletes (class S0: Non-Approved Substances). Testing protocols can detect TB-500 metabolites, so the peptide carries a sanction risk for anyone subject to anti-doping regulations. That status is unchanged.

TB-500 is available through research peptide suppliers and some compounding pharmacies. Quality varies widely among sources, and third-party testing plus proper storage (refrigerated, protected from light) are the standard provenance checks.

Stacking with BPC-157

Why this combination works

BPC-157 and TB-500 address different bottlenecks in the healing cascade. Combined, they produce effects neither achieves alone — the Wolverine Stack.

Perfusion and migration are separate requirements, and each one fails differently on its own. Without perfusion, cells can migrate but lack the nutrients to sustain repair. Without migration, blood supply returns to tissue that repair cells never reach or never organize within.

No head-to-head trial has tested the combination against either compound alone in humans, so the case for pairing them is mechanistic rather than measured.

Wolverine Stack protocol

Cycle: 4-6 weeks for both compounds, then stop and assess.

See BPC-157 + TB-500 Protocol Guide for complete protocol details, weekly scheduling, and troubleshooting.

Other stack options

TB-500 + KPV: When tissue stays inflamed despite repair efforts. KPV silences inflammatory signaling without immunosuppression. Protocol: TB-500 1-2.5 mg 2-3x/week + KPV 250-500 mcg daily.

TB-500 + GHK-Cu: When collagen quality and scar appearance matter. GHK-Cu improves matrix composition during the remodeling phase. Protocol: TB-500 across weeks 1-6, GHK-Cu layered in from weeks 3-12+.

TB-500 + NAD+: When energy is an issue during healing. NAD+ supports mitochondrial function for sustained repair work. Protocol: TB-500 as scheduled + NAD+ 50-200 mg IM, 2-3× weekly, mid-day. Inject NAD+ separately — it is acidic and degrades peptides on contact.

For complex or chronic injuries that don’t respond to the Wolverine Stack alone, see the 5-Compound Injury Protocol.

FAQ

Related Topics

• BPC-157 + TB-500 Protocol Guide — Complete Wolverine Stack protocol
• BPC-157 + TB-500 Dosing Calculator — BAC water and per-vial draw for the Wolverine Stack
• Complete BPC-157 Guide — BPC-157 mechanism, dosing, applications
• 5-Compound Injury Protocol — Extended protocol with NAD+, GHK-Cu, KPV
• Peptide Calculator — Calculate injection volumes from vial concentration
• Where to Inject Peptides — Why local injection matters for TB-500's mass-action mechanism
• Reconstitution Guide — How to prepare peptide vials
• GHK-Cu Guide — Copper peptide for matrix quality and scar appearance
• NAD+ Guide — Cellular energy support for energy-intensive healing
• Injury Recovery Protocol — TB-500 in the 3-tier framework with situational additions
• GLOW & KLOW Protocol — Full 5-compound protocol that includes TB-500

References

¹ Actin sequestration mechanism — Thymosin beta-4 binds G-actin monomers, preventing premature polymerization and maintaining reserve pools for rapid cell migration. Goldstein AL et al. "Thymosin beta4: actin-sequestering protein moonlights to repair injured tissues." Trends Mol Med. 2005;11(9):421-429. PMID 16099219

² Endothelial migration and tube formation — Thymosin beta-4 promotes angiogenesis by enabling endothelial cell migration and capillary structure formation. Philp D et al. "Thymosin beta4 promotes angiogenesis, wound healing, and hair follicle development." Mech Ageing Dev. 2004;125(2):113-115. PMID 15037011

³ Integrin-linked kinase pathway and TGF-beta signaling — Thymosin beta-4 activates ILK, promotes cardiac cell migration and survival, and modulates TGF-beta to reduce fibrosis. Bock-Marquette I et al. "Thymosin beta4 activates integrin-linked kinase and promotes cardiac cell migration, survival, and cardiac repair." Nature. 2004;432(7016):466-472. PMID 15282614

⁴ Macrophage polarization — Thymosin beta-4 promotes shift from pro-inflammatory M1 to reparative M2 macrophage phenotype. Goldstein AL et al. "Thymosin beta4: actin-sequestering protein moonlights to repair injured tissues." Trends Mol Med. 2005;11(9):421-429. PMID 16099219

⁵ Venous ulcer trial — 72 patients across 10 European sites; 0.03% thymosin beta-4 gel produced approximately 25% complete wound closure at 3 months. Treadwell T et al. "Thymosin beta-4 and venous ulcer healing." Ann N Y Acad Sci. 2007. PMID 17495250

⁶ SEER-1 Phase 3 trial — 18 patients with neurotrophic keratopathy; 60% complete corneal healing vs 12.5% placebo; 50% vs 0% maintained healing at Day 43 (p=0.0359). Sosne G et al. "0.1% RGN-259 (Thymosin beta4) Ophthalmic Solution Promotes Healing in Neurotrophic Keratopathy: Phase III Clinical Trial." Int J Mol Sci. 2022. PMC9820614

⁷ Phase 1 safety data — 84 healthy volunteers (54 single-dose, 30 multiple-dose) tolerated recombinant thymosin beta-4 at doses up to 25 μg/kg daily for 10 days with no serious adverse events or dose-limiting toxicity. Wang D et al. "Phase I study of recombinant human thymosin β4." Ann Transl Med. 2021;9(15):1232. PMC8419156

⁸ BPC-157 angiogenic mechanism — VEGFR2-Akt-eNOS signaling, nitric oxide bioavailability, FAK-paxillin cascade. PMC8275860

⁹ TB-500 prodrug metabolism — TB-500 undergoes serial C-terminal cleavage; metabolite Ac-LKKTE showed significant wound healing activity, suggesting TB-500 functions partly as a prodrug. Yang Y et al. Drug Test Anal. 2024;16(10):1248-1258. PMID 38382158

¹⁰ Meprin-alpha/POP processing cascade — POP cannot cleave full-length TB-4 (exceeds ~30 aa structural limit). Meprin-alpha first cuts TB-4 at multiple sites, producing intermediates that POP then processes to release Ac-SDKP. Kumar N, Bhatt DL. "Meprin β metalloproteases release N-acetyl-seryl-aspartyl-lysyl-proline from thymosin β4." Kidney Int. 2016;89(6):1138-1150. PMC4889319

¹¹ Local concentration matters for therapeutic effect — Free systemic TB-4 at the same total dose as a fibrin-targeted nanoparticle formulation produced no functional improvement in cardiac repair — systemic dilution dropped tissue concentration below therapeutic threshold. Targeted delivery achieved 4× dose reduction while improving all endpoints. Huang G et al. "Targeted delivery of thymosin beta 4 to the injured myocardium using CREKA-conjugated nanoparticles." Int J Nanomedicine. 2017;12:3023-3036. PMC5396927

¹² Local sustained delivery in diabetic wound healing — TB-4 encapsulated in collagen-chitosan scaffold achieved controlled local release over 12 days; 93% wound closure at day 21 in diabetic rats with hindlimb ischemia. Faster re-epithelialization, organized collagen fibers, significantly increased CD31-positive vessel density (p<0.05). VEGF/AKT pathway activation confirmed. Ti D et al. "Controlled release of thymosin beta 4 using a collagen-chitosan sponge scaffold augments cutaneous wound healing and increases angiogenesis in diabetic rats with hindlimb ischemia." Tissue Eng Part A. 2015;21(3-4):541-549. PMID 25204972

¹³ TB-500 identification and mislabeling documentation — Confirmed TB-500 is Ac-LKKTETQ (N-terminally acetylated fragment 17-23). Acetylation protects N-terminus from aminopeptidase degradation; C-terminus undergoes serial cleavage. Analysis of commercial products found vials labeled "TB-500" containing full-length TB-4. Esposito S et al. "Synthesis and characterization of the N-terminal acetylated 17-23 fragment of thymosin beta 4 identified in TB-500, a product suspected to be used in horse doping." Drug Test Anal. 2012;4(9):733-738. PMID 22962027

¹⁴ TB-4 biodistribution — Tissue distribution data for synthetic thymosin beta-4 after administration. Mora CA et al. "Biodistribution of synthetic thymosin beta 4 in the serum, urine, and major organs of mice." Int J Immunopharmacol. 1997;19(1):1-8. PMID 9226473

¹⁵ Fragment-specific activities review — Maps TB-4 fragment functions: fragment 17-23 (LKKTETQ) drives angiogenesis and cell migration; fragment 1-4 (Ac-SDKP) suppresses NF-kB and reduces fibrosis; fragment 1-15 inhibits caspases 2/3/8/9 (anti-apoptotic). Xing Y et al. "Progress on the Function and Application of Thymosin β4." Front Endocrinol. 2021;12:767785. PMC8724243

Foundational reviews

¹⁶ Crockford D, Turjman N, et al. "Thymosin beta4: a multi-functional regenerative peptide." Ann N Y Acad Sci. 2017. PMID 28830579

¹⁷ Smart N, Riley PR. "Thymosin beta4 and cardiac repair." Ann N Y Acad Sci. 2012. PMID 22074405

¹⁸ Philp D, Kleinman HK. "Thymosin beta4 promotes dermal healing." Vitam Horm. 2010. PMID 20685922

¹⁹ Sosne G, Qiu P, et al. "Thymosin beta 4 treatment for corneal epithelial wound healing." Ann N Y Acad Sci. 2010. PMID 20016110

²⁰ Bock-Marquette I, Saxena A, et al. "Thymosin beta4 activates integrin-linked kinase and promotes cardiac cell migration, survival and cardiac repair." Nature. 2004. PMID 17507482

²¹ Malinda KM, Sidhu GS, et al. "Thymosin beta 4 activates endothelial cells for angiogenesis and wound healing." J Invest Dermatol. 1999. PMID 19714550